Mylan Says PPI Formulary Impact Unclear As Omeprazole Options Increase
This article was originally published in The Tan Sheet
Executive Summary
Prescription proton pump inhibitor manufacturers are becoming increasingly wary of the effect Prilosec OTC will have on the formulary status of generic offerings
You may also be interested in...
Prilosec OTC Formulation Targeted In Mylan Labs Suit
Mylan Laboratories' lawsuit against Procter & Gamble over the formulation of Prilosec OTC is the most recent in a string of challenges for the over-the-counter heartburn medication
Prilosec OTC Formulation Targeted In Mylan Labs Suit
Mylan Laboratories' lawsuit against Procter & Gamble over the formulation of Prilosec OTC is the most recent in a string of challenges for the over-the-counter heartburn medication
Prilosec OTC Formulation Targeted In Mylan Labs Suit
Mylan Laboratories' lawsuit against Procter & Gamble over the formulation of Prilosec OTC is the most recent in a string of challenges for the over-the-counter heartburn medication